Discontinued — last reported Q3 '21
Diagnostics and Genomics — Share-Based Payment Arrangement, Expense
Agilent Technologies Diagnostics and Genomics — Share-Based Payment Arrangement, Expense remained flat by 0.0% to $7.50M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 36.4%, from $5.50M to $7.50M. Over 3 years (FY 2021 to FY 2024), Diagnostics and Genomics — Share-Based Payment Arrangement, Expense shows an upward trend with a 10.9% CAGR.
Analysis
How to read this metric
An increase may reflect higher talent retention costs or a shift in compensation strategy toward equity-based incentives.
Detailed definition
This represents the non-cash compensation expense recognized for equity-based awards granted to employees within the dia...
Peer comparison
Standard expense item for companies utilizing equity-based compensation to attract and retain specialized talent.
a_segment_diagnostics_and_genomics_share_based_payment_arrangement_expenseHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $22.00M | $25.00M | $22.00M | $30.00M |
| YoY Change | — | +13.6% | -12.0% | +36.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's diagnostics and genomics — share-based payment arrangement, expense?
- Agilent Technologies (A) reported diagnostics and genomics — share-based payment arrangement, expense of $7.50M in Q3 2024.
- How has Agilent Technologies's diagnostics and genomics — share-based payment arrangement, expense changed year-over-year?
- Agilent Technologies's diagnostics and genomics — share-based payment arrangement, expense increased by 36.4% year-over-year, from $5.50M to $7.50M.
- What is the long-term trend for Agilent Technologies's diagnostics and genomics — share-based payment arrangement, expense?
- Over 3 years (2021 to 2024), Agilent Technologies's diagnostics and genomics — share-based payment arrangement, expense has grown at a 10.9% compound annual growth rate (CAGR), from $22.00M to $30.00M.
- What does diagnostics and genomics — share-based payment arrangement, expense mean?
- The non-cash expense related to stock-based compensation for employees in this segment.